Denali Plans to File for Accelerated Approval of Hunter Syndrome DrugZacks Investment Research • 09/04/24
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)GlobeNewsWire • 09/03/24
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing TechnologySeeking Alpha • 08/20/24
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous AdministrationGlobeNewsWire • 08/14/24
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to TradeZacks Investment Research • 08/06/24
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 08/01/24
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?Zacks Investment Research • 07/23/24
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?Zacks Investment Research • 06/24/24
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?Zacks Investment Research • 06/06/24
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesGlobeNewsWire • 06/03/24
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 05/07/24
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialGlobeNewsWire • 05/01/24
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?Zacks Investment Research • 03/28/24
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsGlobeNewsWire • 02/27/24
Denali Therapeutics Announces $500 million Private Placement Equity FinancingGlobeNewsWire • 02/27/24